Based on the INC Research Holdings Inc stock forecast from 0 analysts, the average analyst target price for INC Research Holdings Inc is not available over the next 12 months. INC Research Holdings Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of INC Research Holdings Inc is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, INC Research Holdings Inc’s stock price was USD 2.67. INC Research Holdings Inc’s stock price has changed by +13.14% over the past week, +5.12% over the past month and +23.04% over the last year.
No recent analyst target price found for INC Research Holdings Inc
No recent average analyst rating found for INC Research Holdings Inc
Company Overview INC Research Holdings Inc
Syneos Health, Inc., a contract research organization, provides various clinical development services for the biopharmaceutical and medical device industries in North America, Europe, the Middle East and Africa, the Asia-Pacific, and Latin America. The company offers a range of services focusing on Phase I to Phase IV clinical trials in central nervous system, oncology, and other complex therapeutic areas. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, and regulatory and medical writing; and data services consisting of clinical data management, electronic data capture, and biostatistics. The company's services also comprise strategic and regulatory services, including strategic development services, regulatory consulting and submissions, clinical operations optimization, and pricing and reimbursement planning; and real world and late stage services, such as specialized support for patient registries, safety surveillance studies, prospective observational studies, health outcome research, patient reported outcomes, Phase IV effectiveness trials, and health economics studies and retrospective chart reviews. In addition, it offers functional services, such as data management, medical writing, safety/pharmacovigilance, site contracts, and investigator payments. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Raleigh, North Carolina. Read Less
Syneos Health, Inc., a contract research organization, provides various clinical development services for the biopharmaceutical and medical device industries in North America, Europe, the Middle East and Africa, the Asia-Pacific, and Latin America. The company offers a range of s...Read More
N/A
N/A
6,800
N/A
USD
USA
Adjusted Closing Price for INC Research Holdings Inc (INCR)
Loading...
Unadjusted Closing Price for INC Research Holdings Inc (INCR)
Loading...
Share Trading Volume for INC Research Holdings Inc Shares
Loading...
Compare Performance of INC Research Holdings Inc Shares
Symbol
Capital Gain
Dividend Return
Total Return
Loading...
Loading...
Technical Indicators for INCR
Assets
Top Holdings
N/A
Top Sectors
Top Regions
Stocks Similar To INC Research Holdings Inc (Sector: Other )
Frequently Asked Questions About INC Research Holdings Inc (INCR) Stock
Stock Target Advisor's fundamental analysis for INC Research Holdings Inc's stock is Bearish.
Unfortunately we do not have enough data on INCR's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on INCR's stock to indicate what its average analyst target is.
INCR stock's Price/Earning ratio is 24.30.
Our analysis grades INCR stock's Price / Earning ratio at F. This means that INCR stock's Price/Earning ratio is above 59.00000000000001% of the stocks in the Other sector in the NSD exchange.
Based on this INCR may be a overvalued for its sector.
The last closing price of INCR's stock was USD 2.67.
The most recent market capitalization for INCR is USD -68,994,816.00.
Unfortunately we do not have enough analyst data on INCR's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains INC Research Holdings Inc's stock.
As per our most recent records INC Research Holdings Inc has 6,800 Employees.
Sorry we do not have any infomation available on INC Research Holdings Inc's address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for INCR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
